[go: up one dir, main page]

WO2001032166A1 - NOUVELLE ASSOCIATION CONTENANT UN AGONISTE DU RECEPTEUR ADRENERGIQUE BÉTA2 (β2) ET UN AGONISTE DU RECEPTEUR DE LEUCOTRIENE - Google Patents

NOUVELLE ASSOCIATION CONTENANT UN AGONISTE DU RECEPTEUR ADRENERGIQUE BÉTA2 (β2) ET UN AGONISTE DU RECEPTEUR DE LEUCOTRIENE Download PDF

Info

Publication number
WO2001032166A1
WO2001032166A1 PCT/SE2000/002116 SE0002116W WO0132166A1 WO 2001032166 A1 WO2001032166 A1 WO 2001032166A1 SE 0002116 W SE0002116 W SE 0002116W WO 0132166 A1 WO0132166 A1 WO 0132166A1
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
pharmaceutically acceptable
bambuterol
receptor antagonist
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2000/002116
Other languages
English (en)
Inventor
Jan Trofast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to AU16526/01A priority Critical patent/AU1652601A/en
Publication of WO2001032166A1 publication Critical patent/WO2001032166A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to combinations of pharmaceutically active substances for use in the treatment of inflammatory conditions/disorders, especially respiratory diseases.
  • glucocorticosteroid therapy has been found to be highly effective in the management of asthma, glucocorticosteroids have broad and nonspecific actions and, when taken orally, can produce serious side-effects.
  • Inhaled glucocorticosteroids are much less likely to cause serious side-effects but may still be of concern to some patients.
  • glucocorticosteroids there are factors which can mitigate against the use of inhalers and, in terms of patient drug compliance, s oral administration is generally the favoured route in medical practice.
  • a pharmaceutical composition comprising, in admixture, a first active ingredient which is a beta2 ( ⁇ 2) 5 adrenoreceptor agonist selected from bambuterol and pharmaceutically acceptable derivatives thereof, and a second active ingredient which is a leukotriene receptor antagonist.
  • a pharmaceutically o acceptable derivative of bambuterol means a pharmaceutically acceptable salt or solvate of bambuterol (e.g. bambuterol hydrochloride) or a pharmaceutically acceptable solvate of such a salt.
  • Examples of pharmaceutically acceptable salts include acid addition salts derived from inorganic and organic acids such as a chloride, bromide, sulphate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalene-carboxylate or oleate salt.
  • Examples of pharmaceutically acceptable solvates include hydrates.
  • the invention also provides a pharmaceutical product comprising, in combination, a preparation of a first active ingredient which is a beta2 ( ⁇ 2) adrenoreceptor agonist selected from bambuterol and pharmaceutically acceptable derivatives thereof, and a preparation of a second active ingredient which is a leukotriene receptor antagonist, for simultaneous, sequential or separate use in therapy.
  • a pharmaceutical product comprising, in combination, a preparation of a first active ingredient which is a beta2 ( ⁇ 2) adrenoreceptor agonist selected from bambuterol and pharmaceutically acceptable derivatives thereof, and a preparation of a second active ingredient which is a leukotriene receptor antagonist, for simultaneous, sequential or separate use in therapy.
  • the invention provides a kit comprising a preparation of a first active ingredient which is a beta2 2) adrenoreceptor agonist selected from bambuterol and pharmaceutically acceptable derivatives thereof, a preparation of a second active ingredient which is a leukotriene receptor antagonist, and instructions for the simultaneous, sequential or separate administration of the preparations to a patient in need thereof.
  • a preparation of a first active ingredient which is a beta2 2) adrenoreceptor agonist selected from bambuterol and pharmaceutically acceptable derivatives thereof
  • a preparation of a second active ingredient which is a leukotriene receptor antagonist and instructions for the simultaneous, sequential or separate administration of the preparations to a patient in need thereof.
  • COPD chronic obstructive pulmonary disease
  • asthma such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); rhinitis and rheumatic arthritis.
  • leukotriene receptor antagonists as second active ingredient include: zafirlukast, pranlukast, pobilukast, montelukast (sodium), verlukast, tomelukast, iralukast, L-648,051 (see article by D.J. Tocco et al, Drug Metab. Dispos., 1988, 16(5), 697-700), MK-571 (see article by T.R. Jones et al, Can. J.
  • BI-L-284 a compound proprietary to Boehringer Ingelheim
  • pharmaceutically acceptable derivatives in this context is intended to mean a pharmaceutically acceptable ester, salt or solvate or a pharmaceutically acceptable solvate of such an ester or salt.
  • esters examples include lower alkyl (Cj-Cg alkyl) esters.
  • Pharmaceutically acceptable salts include, where applicable, acid addition salts derived from pharmaceutically acceptable inorganic and organic acids such as a chloride, bromide, sulphate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalene-carboxylate or oleate salt; and salts prepared from pharmaceutically acceptable inorganic and organic bases.
  • acid addition salts derived from pharmaceutically acceptable inorganic and organic acids such as a chloride, bromide, sulphate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-
  • Salts derived from inorganic bases include aluminium, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and bismuth salts. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts.
  • Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, cyclic amines like arginine, betaine, choline and the like.
  • Examples of pharmaceutically acceptable solvates include hydrates.
  • Certain of the active ingredients used in the present invention are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the active ingredients and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.
  • Preferred combinations of first and second active ingredients include bambuterol/zafirlukast, bambuterol/montelukast sodium, bambuterol/pranlukast, bambuterol hydrochloride/zafirlukast, bambuterol hydrochloride/montelukast sodium and bambuterol hydrochloride/pranlukast.
  • the pharmaceutical composition of the invention may be prepared by mixing the first active ingredient with the second active ingredient. Therefore, in a further aspect of the present invention, there is provided a process for the preparation of a pharmaceutical composition which comprises mixing a first active ingredient which is a beta2 ( ⁇ 2) adrenoreceptor agonist selected from bambuterol and pharmaceutically acceptable derivatives thereof, with a second active ingredient which is a leukotriene receptor antagonist.
  • a first active ingredient which is a beta2 ( ⁇ 2) adrenoreceptor agonist selected from bambuterol and pharmaceutically acceptable derivatives thereof.
  • the first and second active ingredients may alternatively be administered simultaneously (other than in admixture as described above), sequentially or separately to treat inflammatory conditions.
  • sequential is meant that the first and second active ingredients are administered one immediately after the other. They still have the desired effect if they are administered separately but less than about 4 hours apart, preferably less than about 2 hours apart, more preferably less than about 30 minutes apart.
  • the active ingredients may, and indeed usually will, be used in admixture with one or more pharmaceutically acceptable ingredients which may be selected, for example, from adjuvants, carriers, binders, lubricants, diluents, stabilising agents, buffering agents, emulsifying agents, viscosity-regulating agents, surfactants, preservatives, flavourings and colorants.
  • pharmaceutically acceptable ingredients which may be selected, for example, from adjuvants, carriers, binders, lubricants, diluents, stabilising agents, buffering agents, emulsifying agents, viscosity-regulating agents, surfactants, preservatives, flavourings and colorants.
  • the dosages administered will, of course, vary with the first and second active ingredients employed, the mode of administration, the treatment desired and the disorder indicated.
  • satisfactory results will be obtained when the total daily oral dosage of first active ingredient(s) is in the range from 1 to 50 mg, particularly from 1, 2, 3, 4 or 5 to 40, preferably to 30, more preferably to 20 mg, and the total daily oral dosage of second active ingredient(s) is in the range from 1 to 200 mg, preferably from 1, 5 or 10 to 150, more preferably to 100, even more preferably to 80 or 50 mg.
  • the pharmaceutical composition, pharmaceutical product or kit according to the invention may be administered as divided doses from 1 to 4 times a day, and preferably once or twice a day.
  • the first and second active ingredients are conveniently administered systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions.
  • Aqueous suspensions or, preferably, solutions may also be employed, with or without a suitable pH and/or tonicity adjustment, either as a unit-dose or multi-dose formulations.
  • Tablets and gelatin capsules, which may be coated if desired, containing the active ingredient(s) may, for example, also include one or more diluents, carriers, binders, lubricants or stabilising agents.
  • Injectable solutions of the active ingredient(s) may also contain, for example, one or more preservatives, stabilising agents, viscosity-regulating agents, emulsifying agents or buffering agents.
  • the present invention further provides the use of a pharmaceutical composition, pharmaceutical product or kit according to the invention in the manufacture of a medicament for the treatment of an inflammatory disorder.
  • the present invention provides a method of treating an inflammatory disorder which comprises administering a therapeutically effective amount of a pharmaceutical composition of the invention to a patient in need thereof.
  • the present invention provides a method of treating an inflammatory disorder which comprises simultaneously, sequentially or separately administering: (a) a (therapeutically effective) dose of a first active ingredient which is a beta2 ( ⁇ 2) adrenoreceptor agonist selected from bambuterol and pharmaceutically acceptable derivatives thereof; and
  • the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary.
  • the terms “therapeutic” and “therapeutically” should be construed accordingly.
  • Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question.
  • Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique, un produit ou un kit pharmaceutique comprenant un premier composant actif qui est un agoniste du récepteur adrénergique béta2 (β2) et un deuxième composant actif qui est un antagoniste du récepteur de leucotriène. Cette composition est destinée à être utilisée dans le traitement de troubles inflammatoires.
PCT/SE2000/002116 1999-11-03 2000-10-27 NOUVELLE ASSOCIATION CONTENANT UN AGONISTE DU RECEPTEUR ADRENERGIQUE BÉTA2 (β2) ET UN AGONISTE DU RECEPTEUR DE LEUCOTRIENE Ceased WO2001032166A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16526/01A AU1652601A (en) 1999-11-03 2000-10-27 New combination comprising a beta2-adrenoreceptor agonist and a leukotriene receptor antagonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903995-0 1999-11-03
SE9903995A SE9903995D0 (sv) 1999-11-03 1999-11-03 New combination

Publications (1)

Publication Number Publication Date
WO2001032166A1 true WO2001032166A1 (fr) 2001-05-10

Family

ID=20417605

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/SE2000/002115 Ceased WO2001032163A1 (fr) 1999-11-03 2000-10-27 NOUVELLE ASSOCIATION CONTENANT UN AGONISTE DE L'ADRENORECEPTEUR BETA2 (β2) ET UN ANTAGONISTE DU RECEPTEUR DE LEUCOTRIENE
PCT/SE2000/002116 Ceased WO2001032166A1 (fr) 1999-11-03 2000-10-27 NOUVELLE ASSOCIATION CONTENANT UN AGONISTE DU RECEPTEUR ADRENERGIQUE BÉTA2 (β2) ET UN AGONISTE DU RECEPTEUR DE LEUCOTRIENE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/SE2000/002115 Ceased WO2001032163A1 (fr) 1999-11-03 2000-10-27 NOUVELLE ASSOCIATION CONTENANT UN AGONISTE DE L'ADRENORECEPTEUR BETA2 (β2) ET UN ANTAGONISTE DU RECEPTEUR DE LEUCOTRIENE

Country Status (13)

Country Link
EP (1) EP1242065A1 (fr)
JP (1) JP2003513037A (fr)
KR (1) KR20020050254A (fr)
CN (1) CN1387431A (fr)
AU (2) AU1652601A (fr)
BR (1) BR0015172A (fr)
CA (1) CA2388657A1 (fr)
IL (1) IL149365A0 (fr)
MX (1) MXPA02004334A (fr)
NO (1) NO20022103L (fr)
SE (1) SE9903995D0 (fr)
WO (2) WO2001032163A1 (fr)
ZA (1) ZA200203178B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
AR040962A1 (es) * 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
JP2007531743A (ja) * 2004-04-05 2007-11-08 セプラコア インコーポレーテッド 他の薬剤と組合せた（ｒ，ｒ）−ホルモテロール
ES2245612B1 (es) * 2004-06-29 2007-08-16 Universidad De Barcelona Nuevo uso terapeutico del formoterol.
CN101128196B (zh) * 2005-03-16 2013-01-02 Meda制药有限及两合公司 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合
SG195319A1 (en) * 2011-06-06 2013-12-30 Chiesi Farma Spa Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
KR102192739B1 (ko) * 2012-12-05 2020-12-18 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
JP5846185B2 (ja) 2013-11-21 2016-01-20 大日本印刷株式会社 貫通電極基板及び貫通電極基板を用いた半導体装置
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027981A1 (fr) * 1996-12-20 1998-07-02 Astra Aktiebolag (Publ) Formulation aqueuse comprenant du bambuterol et son utilisation
WO1998039970A1 (fr) * 1997-03-13 1998-09-17 Merck & Co., Inc. Antagonistes des leucotrienes a base de quinoline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704644D0 (sv) * 1997-12-12 1997-12-12 Astra Ab New use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027981A1 (fr) * 1996-12-20 1998-07-02 Astra Aktiebolag (Publ) Formulation aqueuse comprenant du bambuterol et son utilisation
WO1998039970A1 (fr) * 1997-03-13 1998-09-17 Merck & Co., Inc. Antagonistes des leucotrienes a base de quinoline

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRIAN J. LIPWORTH ET AL.: "Effects of adding a leukotriene antagonist or a long-acting beta2-agonist in asthmatic patients with the glycine-16 beta2-adrenoceptor genotype", AM. J. MED., vol. 109, 2000, pages 114 - 121 *
JEAN-FRANCOIS DESSANGES ET AL.: "The effect of zafirlukast on repetitive exercise-induced bronchoconstriction: The possible role of leukotrienes in exercise-induced refractoriness", J. ALLERGY CLIN. IMMUNOL., vol. 104, no. 6, 1999, pages 1155 - 1161 *
JONATHAN A. LEFF ET AL.: "Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction", N. ENGL. J. MED., vol. 339, no. 3, 1998, pages 147 - 152 *
OWEN J. DEMPSEY ET AL.: "Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids", CHEST, vol. 117, 2000, pages 950 - 953 *

Also Published As

Publication number Publication date
WO2001032163A1 (fr) 2001-05-10
AU1652601A (en) 2001-05-14
KR20020050254A (ko) 2002-06-26
IL149365A0 (en) 2002-11-10
AU1321401A (en) 2001-05-14
MXPA02004334A (es) 2002-11-07
ZA200203178B (en) 2003-07-22
NO20022103D0 (no) 2002-05-02
BR0015172A (pt) 2002-06-18
EP1242065A1 (fr) 2002-09-25
CA2388657A1 (fr) 2001-05-10
JP2003513037A (ja) 2003-04-08
NO20022103L (no) 2002-05-02
CN1387431A (zh) 2002-12-25
SE9903995D0 (sv) 1999-11-03

Similar Documents

Publication Publication Date Title
AU2004216472B2 (en) Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
WO2001032166A1 (fr) NOUVELLE ASSOCIATION CONTENANT UN AGONISTE DU RECEPTEUR ADRENERGIQUE BÉTA2 (β2) ET UN AGONISTE DU RECEPTEUR DE LEUCOTRIENE
JP2002534380A (ja) Ｍｅｋ阻害剤による喘息の治療
JP2008297311A (ja) 気道疾患の処置のためのプレコナリルを含む薬学的処方物
JP5208473B2 (ja) アゼラスチンと抗コリン薬を含有する医薬組成物
EP1078629A2 (fr) Utilisation du Salmeterol ou ses sels dans le traitement de l'allergie et de l'inflammation
JP2008509143A5 (fr)
US5290815A (en) Treatment of inflammation and allergy
AU2005240404A1 (en) Treating respiratory diseases with gycopyrrolate and analogues
US20060110449A1 (en) Pharmaceutical composition
US20060189642A1 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
EP1567139A1 (fr) Nouvelle combinaison synergique contenant du roflumilast et du formoterol
JP5091474B2 (ja) フドステインと抗コリン薬を含有する医薬組成物
KR20130140672A (ko) 기침 치료용 카보네이트 유도체
WO2010071581A1 (fr) Produit pharmaceutique comprenant un antagoniste de récepteur muscarinique et un agoniste de b2-adrénocepteur
JP2016504358A (ja) オキシブチニンを投与するための方法および組成物
JPH04226916A (ja) ベンゾシクロヘプタチオフェンカルボン酸誘導体の新規医薬用途
WO2007008157A1 (fr) Nouvelle combinaison 2
Boothe Plugs, bugs and drugs: treating the respiratory tract.
JP2007126441A (ja) 杯細胞過形成抑制のための医薬組成物
EP0526638A1 (fr) Medicament pour syndromes respiratoires obstructifs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP